Thrombotic thrombocytopenic purpura natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(8 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Xyz}}
{{Thrombotic thrombocytopenic purpura }}


{{CMG}}; {{AE}}  
{{CMG}}; {{AE}} {{S.G.}}


==Overview==
==Overview==
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
If left untreated, >90% of patients with TTP may progress to develop [[Kidney|renal]] dysfunction, [[neurological disorders]] (mild [[headache]], onset of [[behavioural]] anomalies, [[transient]] [[sensory]] and [[Motor neuron disease|motor]] deficits, [[coma]]), [[Ischemia|ischaemic]] [[gastrointestinal]] [[complications]] ([[abdominal pain]]) and [[retinal detachment]].
 
OR
 
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
 
OR
 
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==


===Natural History===
===Natural History===
*The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
*The [[Symptom|symptoms]] of TTP([[Acquired disorder|acquired]]) usually develop in the 4th decade of life, and start with no specificity of the [[Medical sign|signs]], [[symptom]]<nowiki/>s and [[laboratory]] findings; [[Symptom|symptoms]] such as [[fever]], [[Kidney|renal]] dysfunction, [[neurological disorders]] (mild [[headache]], onset of [[behavioural]] anomalies, [[transient]] [[sensory]] and [[Motor neuron disease|motor]] deficits, [[coma]]), [[Ischemia|ischaemic]] [[gastrointestinal]] [[complications]] ([[abdominal pain]]) and [[retinal detachment]].<ref name="pmid227902582">{{cite journal |vauthors=Rizzo C, Rizzo S, Scirè E, Di Bona D, Ingrassia C, Franco G, Bono R, Quintini G, Caruso C |title=Thrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchange |journal=Blood Transfus |volume=10 |issue=4 |pages=521–32 |date=October 2012 |pmid=22790258 |pmc=3496241 |doi=10.2450/2012.0122-11 |url=}}</ref>
*The symptoms of (disease name) typically develop ___ years after exposure to ___.  
*[[Neurological]] [[symptoms]] at onset  do not occur approximately more than 35% of patients.
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
*[[Fever]] and [[Renal insufficiency|renal dysfunction]] are present among only a small [[Minority group|minority]] of [[Patient|patients]].
*The [[Symptom|symptoms]] of TTP typically develop after 40 years.  


===Complications===
===Complications===
*Common complications of [disease name] include:
*Common [[Complication (medicine)|complications]] of TTP([[Restriction|restrict]] [[blood]] [[flow]] to [[Organ (anatomy)|organs]] such as the [[brain]], [[Kidney|kidneys]], and [[heart]]) include:<ref name="pmid227902582" /><ref name="pmid226245963">{{cite journal |vauthors=Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ |title=Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies |journal=Br. J. Haematol. |volume=158 |issue=3 |pages=323–35 |date=August 2012 |pmid=22624596 |doi=10.1111/j.1365-2141.2012.09167.x |url=}}</ref>
**[Complication 1]
**Early death in approximilaty of patients are not diagnosed.
**[Complication 2]
**[[Neurological]] problems([[personality changes]],mild [[Headache|headaches]], [[confusion]] and [[slurred speech]], [[coma]])
**[Complication 3]
**Abnormal [[kidney]] [[Function (biology)|function]]
**[[Heart]] problems


===Prognosis===
===Prognosis===
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
* The mortality rate is approximately 90% for untreated cases, but the [[prognosis]] is reasonably favorable (80-90%) for patients with [[idiopathic]] TTP diagnosed and treated early with [[plasmapheresis]].<ref name="pmid226245963" />
*Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
* Approximately one-third of patients experiencing a TTP episode have a relapse within 10 years following their first attack.
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
* Secondary TTP still has a dismal prognosis, with [[Mortality rate|mortality]] rates despite treatment being reported as 59% to 100%.
*[Subtype of disease/malignancy] is associated with the most favorable prognosis.
*The prognosis
 
The mortality rate is approximately 95% for untreated cases, but the prognosis is reasonably favorable (80-90%) for patients with idiopathic TTP diagnosed and treated early with [[plasmapheresis]].
 
Approximately one-third of patients experiencing a TTP episode have a relapse within 10 years following their first attack.
 
Secondary TTP still has a dismal prognosis, with mortality rates despite treatment being reported as 59% to 100%.
 
 
 


==References==
==References==

Latest revision as of 14:09, 31 March 2019

Thrombotic thrombocytopenic purpura Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombotic thrombocytopenic purpura from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Peripheral Smear

Direct Coombs Test

von Willebrand Factor-cleaving Protease Activity

X-ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombotic thrombocytopenic purpura natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombotic thrombocytopenic purpura natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombotic thrombocytopenic purpura natural history, complications and prognosis

CDC on Thrombotic thrombocytopenic purpura natural history, complications and prognosis

Thrombotic thrombocytopenic purpura natural history, complications and prognosis in the news

Blogs on Thrombotic thrombocytopenic purpura natural history, complications and prognosis

Directions to Hospitals Treating Thrombotic thrombocytopenic purpura

Risk calculators and risk factors for Thrombotic thrombocytopenic purpura natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

If left untreated, >90% of patients with TTP may progress to develop renal dysfunction, neurological disorders (mild headache, onset of behavioural anomalies, transient sensory and motor deficits, coma), ischaemic gastrointestinal complications (abdominal pain) and retinal detachment.

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

  • The mortality rate is approximately 90% for untreated cases, but the prognosis is reasonably favorable (80-90%) for patients with idiopathic TTP diagnosed and treated early with plasmapheresis.[2]
  • Approximately one-third of patients experiencing a TTP episode have a relapse within 10 years following their first attack.
  • Secondary TTP still has a dismal prognosis, with mortality rates despite treatment being reported as 59% to 100%.

References

  1. 1.0 1.1 Rizzo C, Rizzo S, Scirè E, Di Bona D, Ingrassia C, Franco G, Bono R, Quintini G, Caruso C (October 2012). "Thrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchange". Blood Transfus. 10 (4): 521–32. doi:10.2450/2012.0122-11. PMC 3496241. PMID 22790258.
  2. 2.0 2.1 Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ (August 2012). "Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies". Br. J. Haematol. 158 (3): 323–35. doi:10.1111/j.1365-2141.2012.09167.x. PMID 22624596.

Template:WH Template:WS